The Latest Breaking News from Roche

Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its weight-loss drug.

Roche agrees to acquire Poseida Therapeutics for $1.5 billion, expanding its CAR-T therapy platform with a focus on hematologic malignancies and solid tumors.

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

The stock market rally revived with the major indexes reclaiming key levels and many top leaders flashing buy signals.

The first self-administered tests for collecting vaginal samples are on the way to health care facilities, making Pap smears more accessible and tolerable.

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

TG Therapeutics stock broke out Monday less than two weeks after the biotech company reported a surprise profit for the June quarter.

Roche is working on bringing its weight-loss medications to patients "faster than anticipated,” making it yet another contender in the weight-loss drug market.